CO2020002961A2 - Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre - Google Patents

Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre

Info

Publication number
CO2020002961A2
CO2020002961A2 CONC2020/0002961A CO2020002961A CO2020002961A2 CO 2020002961 A2 CO2020002961 A2 CO 2020002961A2 CO 2020002961 A CO2020002961 A CO 2020002961A CO 2020002961 A2 CO2020002961 A2 CO 2020002961A2
Authority
CO
Colombia
Prior art keywords
treatment
pyruvate kinase
blood disorders
kinase activators
activators
Prior art date
Application number
CONC2020/0002961A
Other languages
English (en)
Inventor
Giovanni Cianchetta
Tao Liu
Anil Kumar Padyana
Zhihua Sui
Zhenwei Cai
Dawei Cui
Jingjing Ji
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CO2020002961A2 publication Critical patent/CO2020002961A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos que activan la piruvato quinasa, composiciones farmacéuticas y métodos para usarlos. Estos compuestos están representados por la fórmula (I): (I), donde R1, R2, Ra, Rb, Rj, Rk y Q son como se los define en la presente.
CONC2020/0002961A 2017-08-15 2020-03-12 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre CO2020002961A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Publications (1)

Publication Number Publication Date
CO2020002961A2 true CO2020002961A2 (es) 2020-04-13

Family

ID=63524352

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2020/0002959A CO2020002959A2 (es) 2017-08-15 2020-03-12 Moduladores de piruvato quinasas y uso de los mismos
CONC2020/0002961A CO2020002961A2 (es) 2017-08-15 2020-03-12 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CONC2020/0002959A CO2020002959A2 (es) 2017-08-15 2020-03-12 Moduladores de piruvato quinasas y uso de los mismos

Country Status (32)

Country Link
US (7) US11464775B2 (es)
EP (4) EP3668881B1 (es)
JP (4) JP7275107B2 (es)
KR (3) KR102642408B1 (es)
CN (3) CN117186119A (es)
AU (3) AU2018316587B2 (es)
BR (2) BR112020003254A2 (es)
CA (2) CA3072455A1 (es)
CL (1) CL2020000375A1 (es)
CO (2) CO2020002959A2 (es)
CR (1) CR20200123A (es)
CY (1) CY1124953T1 (es)
DK (2) DK3668513T3 (es)
EC (1) ECSP20018487A (es)
ES (3) ES2905100T3 (es)
FI (1) FI3668512T3 (es)
HR (2) HRP20220039T1 (es)
HU (2) HUE061910T2 (es)
IL (3) IL272599B (es)
LT (2) LT3668513T (es)
MD (1) MD3668513T2 (es)
MX (2) MX2020001832A (es)
PE (1) PE20200724A1 (es)
PH (1) PH12020500343A1 (es)
PL (2) PL3668513T3 (es)
PT (2) PT3668513T (es)
RS (2) RS64221B1 (es)
SG (2) SG11202001353PA (es)
SI (2) SI3668512T1 (es)
TW (3) TWI823580B (es)
UA (1) UA126292C2 (es)
WO (3) WO2019035864A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311897B (zh) 2017-03-20 2021-07-20 福马治疗股份有限公司 作为丙酮酸激酶(pkr)活化剂的吡咯并吡咯组合物
CA3072455A1 (en) 2017-08-15 2019-02-21 Agios Pharmaceuticals, Inc. Pyruvate kinase modulators and use thereof
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
JP2022520090A (ja) * 2019-02-13 2022-03-28 アジオス ファーマシューティカルズ， インコーポレイテッド チエノ［３，２－ｂ］ピロール［３，２－ｄ］ピリダジノン誘導体、および癌、肥満および糖尿病関連障害の治療のためのｐｋｍ２誘導体としてのその使用
KR20220025814A (ko) * 2019-06-26 2022-03-03 닛산 가가쿠 가부시키가이샤 전하 수송성 바니시
AU2021311597A1 (en) * 2020-07-21 2023-02-02 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
WO2023052783A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
AU2022390088A1 (en) * 2021-11-16 2024-05-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
IL147757A0 (en) 1999-07-30 2002-08-14 Abbott Gmbh & Co Kg 2-pyrazolin-5-ones
HUP0202725A3 (en) 1999-09-04 2005-04-28 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity, process for their preparation and pharmaceutical compositions containing them
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN102159574A (zh) * 2008-07-23 2011-08-17 沃泰克斯药物股份有限公司 三-环吡唑并吡啶激酶抑制剂
US8420649B2 (en) * 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
US8841305B2 (en) * 2008-10-09 2014-09-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of the human pyruvate kinase M2 receptor
WO2010118063A2 (en) * 2009-04-06 2010-10-14 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
ES2632954T3 (es) 2009-06-29 2017-09-18 Agios Pharmaceuticals, Inc. Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa
CA2797694A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Activators of human pyruvate kinase
JP5886310B2 (ja) 2010-12-06 2016-03-16 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
SG194697A1 (en) * 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
WO2012151448A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
ES2668213T3 (es) 2011-05-03 2018-05-17 Agios Pharmaceuticals, Inc. Uso de activadores de piruvato quinasa para aumentar la vida útil de los glóbulos rojos de la sangre y tratar la anemia
CN103608016A (zh) * 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
EP2734520B1 (en) * 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
US9458132B2 (en) 2012-11-08 2016-10-04 Agios Pharmaceuticals, Inc Therapeutic compounds and compositions and their use as PKM2 modulators
WO2014118135A1 (en) * 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
BR112015023328A2 (pt) * 2013-03-13 2017-07-18 Flatley Discovery Lab compostos de piridazinona e métodos para o tratamento de fibrose cística
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
WO2019008025A1 (en) 2017-07-07 2019-01-10 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
CA3072455A1 (en) 2017-08-15 2019-02-21 Agios Pharmaceuticals, Inc. Pyruvate kinase modulators and use thereof
UY37843A (es) 2017-08-15 2019-03-29 Abbvie Inc Inhibidores de mcl-1 macrocíclicos y métodos de uso
JP2022520090A (ja) * 2019-02-13 2022-03-28 アジオス ファーマシューティカルズ， インコーポレイテッド チエノ［３，２－ｂ］ピロール［３，２－ｄ］ピリダジノン誘導体、および癌、肥満および糖尿病関連障害の治療のためのｐｋｍ２誘導体としてのその使用

Also Published As

Publication number Publication date
MX2020001833A (es) 2020-07-22
UA126292C2 (uk) 2022-09-14
IL292530A (en) 2022-06-01
WO2019035864A1 (en) 2019-02-21
MX2020001832A (es) 2020-07-22
ES2944545T3 (es) 2023-06-22
RU2020110573A (ru) 2021-09-16
US20220233541A1 (en) 2022-07-28
EP3668512A1 (en) 2020-06-24
PE20200724A1 (es) 2020-07-21
US11464775B2 (en) 2022-10-11
PL3668512T3 (pl) 2023-06-19
WO2019035863A8 (en) 2019-03-28
RU2020110573A3 (es) 2021-12-24
JP2023052478A (ja) 2023-04-11
ES2905100T3 (es) 2022-04-07
EP3668512B1 (en) 2023-02-15
IL272599A (en) 2020-03-31
US11872225B2 (en) 2024-01-16
TW201919631A (zh) 2019-06-01
WO2019035864A8 (en) 2019-03-28
CR20200123A (es) 2020-06-29
PT3668512T (pt) 2023-05-22
WO2019035865A8 (en) 2019-03-28
JP2023027276A (ja) 2023-03-01
SI3668512T1 (sl) 2023-06-30
RS64221B1 (sr) 2023-06-30
US11040036B2 (en) 2021-06-22
IL292530B2 (en) 2023-06-01
TW201920203A (zh) 2019-06-01
IL272599B (en) 2022-08-01
CA3072455A1 (en) 2019-02-21
FI3668512T3 (fi) 2023-05-12
ES2966825T3 (es) 2024-04-24
RS62871B1 (sr) 2022-02-28
KR20230127364A (ko) 2023-08-31
US20200206225A1 (en) 2020-07-02
DK3668513T3 (da) 2022-01-10
PH12020500343A1 (en) 2021-02-08
EP4026838A1 (en) 2022-07-13
SG11202001353PA (en) 2020-03-30
TWI796353B (zh) 2023-03-21
IL272597B (en) 2022-06-01
US20210130371A1 (en) 2021-05-06
LT3668513T (lt) 2022-03-25
AU2018316588B2 (en) 2023-02-02
US11957680B2 (en) 2024-04-16
CN111032045A (zh) 2020-04-17
JP2020531432A (ja) 2020-11-05
ECSP20018487A (es) 2020-05-29
TW202323258A (zh) 2023-06-16
CN117186119A (zh) 2023-12-08
BR112020003254A2 (pt) 2020-10-27
EP3668513B1 (en) 2021-11-10
EP3668513A1 (en) 2020-06-24
US11364240B2 (en) 2022-06-21
SG11202001262QA (en) 2020-03-30
AU2018316587B2 (en) 2023-05-11
JP7301040B2 (ja) 2023-06-30
BR112020003262A2 (pt) 2020-09-01
KR20200054200A (ko) 2020-05-19
US20200207785A1 (en) 2020-07-02
CA3071993A1 (en) 2019-02-21
HRP20230452T1 (hr) 2023-07-21
CN111032045B (zh) 2023-08-15
HUE061910T2 (hu) 2023-08-28
JP7275107B2 (ja) 2023-05-17
IL272597A (en) 2020-03-31
DK3668512T3 (da) 2023-05-22
EP3668881A1 (en) 2020-06-24
PL3668513T3 (pl) 2022-03-21
CN111032046A (zh) 2020-04-17
AU2023202772A1 (en) 2023-05-18
KR102642408B1 (ko) 2024-02-28
CN111032046B (zh) 2023-09-26
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
CL2020000375A1 (es) 2020-12-11
US20210077490A1 (en) 2021-03-18
HUE057178T2 (hu) 2022-04-28
JP2020531443A (ja) 2020-11-05
AU2018316588A1 (en) 2020-02-20
KR20200054199A (ko) 2020-05-19
US20220395503A1 (en) 2022-12-15
CY1124953T1 (el) 2023-01-05
MD3668513T2 (ro) 2022-04-30
TWI790271B (zh) 2023-01-21
WO2019035863A1 (en) 2019-02-21
US11590132B2 (en) 2023-02-28
EP3668881B1 (en) 2023-10-04
HRP20220039T1 (hr) 2022-04-15
AU2018316587A1 (en) 2020-02-20
CO2020002959A2 (es) 2020-04-13
WO2019035865A1 (en) 2019-02-21
LT3668512T (lt) 2023-06-12
US20230226055A1 (en) 2023-07-20
SI3668513T1 (sl) 2022-04-29

Similar Documents

Publication Publication Date Title
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CU20180044A7 (es) Derivados novedosos de diamino piridina
CL2015003037A1 (es) Derivados de triazina
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
UY36464A (es) Compuestos de quinazolina